Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Basically, it mimics and boosts those signals
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
Kanaan RA, Oliver G, Dharan A, Sendi S, Maier A, Mohebbi M, et al
A profound comprehension of the physiological function of intestinal homeostasis and permeability is essential to more accurately evaluate the prospective application of GLP-1 RAs in patients with ongoing inflammation
US$ 21.76
US$ 23.64
US$ 21.58
US$ 24.09
US$ 24.37
US$ 26.63
US$ 26.24
US$ 22.37
US$ 21.97
US$ 27.40
US$ 21.87
US$ 20.54
US$ 29.75
%20(1).png)
